XMT 2056
Alternative Names: XMT-2056Latest Information Update: 30 Sep 2025
At a glance
- Originator Mersana Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Sep 2025 XMT 2056 is still in phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT05514717)
- 31 Dec 2024 Mersana Therapeutics has patent pending applications in the US
- 31 Dec 2024 Mersana Therapeutics has patent protection for "compositions of matter and methods of use" and 2041 "compositions of matter"